A new trading day began on Tuesday, with Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock price down -0.28% from the previous day of trading, before settling in for the closing price of $3.57. XERS’s price has ranged from $1.69 to $3.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 241.10% over the last five years. Meanwhile, its annual earnings per share averaged 20.19%. With a float of $137.81 million, this company’s outstanding shares have now reached $149.00 million.
The firm has a total of 377 workers. Let’s measure their productivity. In terms of profitability, gross margin is 77.02%, operating margin of -24.11%, and the pretax margin is -35.02%.
Xeris Biopharma Holdings Inc (XERS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc is 7.56%, while institutional ownership is 44.37%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.19% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Here are Xeris Biopharma Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Analysing the last 5-days average volume posted by the [Xeris Biopharma Holdings Inc, XERS], we can find that recorded value of 1.4 million was lower than the volume posted last year of 1.49 million. As of the previous 9 days, the stock’s Stochastic %D was 36.26%. Additionally, its Average True Range was 0.16.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 73.73%, which indicates a significant increase from 59.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.04% in the past 14 days, which was lower than the 41.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.46, while its 200-day Moving Average is $2.78. Now, the first resistance to watch is $3.61. This is followed by the second major resistance level at $3.66. The third major resistance level sits at $3.74. If the price goes on to break the first support level at $3.48, it is likely to go to the next support level at $3.40. Now, if the price goes above the second support level, the third support stands at $3.35.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
With a market capitalization of 530.73 million, the company has a total of 149,081K Shares Outstanding. Currently, annual sales are 163,910 K while annual income is -62,260 K. The company’s previous quarter sales were 54,270 K while its latest quarter income was -15,740 K.
